Inhibrx Biosciences, Inc. Common Stock
INBX · Biotechnology · $1.6B
Powering up
Not on a screen at the moment — no base, so no pivot to draw. The price and volume are below.
9-dayabout two weeks21-dayabout a month50-dayabout a quarter200-dayabout a year
The read
Inhibrx Biosciences, Inc. Common Stock is not on any of the screens right now. Its relative strength rating is 97, and it sits in Biotechnology.
Peers
Catalyst roadmap
Nothing dated in the next three months that we can ingest automatically.
Flagged by the market sweep
Large insider purchaseFiling · 2026-09-18
Kayyem Jon Faiz $500,000
Several insiders boughtInsider · 2026-09-18
3 insiders, $3,999,597 in 30d
Several insiders boughtInsider · 2026-09-17
3 insiders, $3,499,597 in 30d
Several insiders boughtInsider · 2026-09-16
3 insiders, $3,499,597 in 30d
Several insiders boughtInsider · 2026-09-15
3 insiders, $3,499,597 in 30d
Several insiders boughtInsider · 2026-09-12
3 insiders, $3,499,597 in 30d
Several insiders boughtInsider · 2026-09-11
3 insiders, $3,499,597 in 30d
From a separate overnight market sweep, not from the screens on this site. What it flagged, not what it means.
In the news
Chondrosarcoma Clinical Trial Pipeline: Emerging Therapies and Key Developments Shaping the Treatment Landscape | DelveInsightGlobeNewswire Inc. · 2026-09-01
Headlines link to the publisher. We do not host, summarise or rank them, and a headline appearing here is not a view about the company.
Insiders
No Form 4 filings read for this company in the last six months. That can mean nobody filed, or that this name has not been on a screen long enough for us to have fetched them.
X-ray